The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025 Phase III Clinical ...

SHANGHAI, China I 19, 2024 I Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, ...

Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

In the trial, the therapy was given to 36 patients via a one-off intravenous infusion. Results showed that it is safe in the ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...

The GLORIOUS trial found that an intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) during heart surgeries ...

Myasthenia gravis treatment aims to minimize the effects of muscle weakness due to an immune process. It includes medications ...

The medical infusion center will treat over 50 conditions by administering medicine directly into a patient’s bloodstream ...

Total research and development expenses for the three months ended September 30, 2024 were $3.0 million, compared to $0.5 million for the three months ended September 30, 2023. This increase of $2.5 ...